Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

Phase 3CardiolRxPositive

AI Analysis

Summary

Cardiol Therapeutics announced that its Phase 3 MAVERIC trial achieved its original 110-patient enrollment target ahead of the September 2026 guidance and will expand enrollment to up to 150 patients to strengthen efficacy assessment of CardiolRx. The trial expansion was recommended by the MAVERIC Steering Committee to capture sufficient events for robust evaluation of the drug's potential to reduce recurrence risk.

Clinical Trial Data

Phase

Phase 3

Patients

150

Outcome Details

Enrollment target of 110 patients achieved ahead of schedule; trial expanded to up to 150 patients

Importance:6/10

Sentiment:

0.70

Phase 3enrollmentCardiolRxMAVERIC trialahead of schedule

Related Companies

$CRDL

Read the original article

Published by PR Newswire Biotech on September 23, 2026 10:00 AM

Read Original